04:58 PM EST, 03/05/2024 (MT Newswires) -- Gilead Sciences ( GILD ) said late Tuesday that new results from three retrospective studies support the use of Veklury for people hospitalized with COVID-19.

One of the studies demonstrated that Veklury was "associated with a reduced risk of certain long-COVID symptoms in people who were hospitalized for COVID-19," the company said.

Another study showed that the medication was "associated with significantly reduced mortality among immunocompromised people and hospitalized for COVID-19 during the Omicron period," Gilead said.

A third study showed that "treatment with Veklury and dexamethasone among patients hospitalized for COVID-19 was associated with reduced mortality compared to treatment with only dexamethasone, irrespective of oxygen requirements," it said.

The company said the results are being presented at the Conference on Retroviruses and Opportunistic Infections.

Price: 72.9, Change: -0.09, Percent Change: -0.12